Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection RESEARCH TRIANGLE PARK, NC, December 11, 2007 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the
Merial To Screen Chimerix' Chemical Library For Animal Health Drug Leads DULUTH, GA, and RESEARCH TRIANGLE PARK, NC, January 29, 2007 - Merial Limited and Chimerix, Inc. announced today that they have signed an agreement under which Merial will screen a Chimerix chemical library for animal health
Chimerix Announced Initiation of Phase I clinical trials of CMX001, An Oral Treatment for Smallpox Infection RESEARCH TRIANGLE PARK, NC, June 28 2006 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that it has received U.S.
Chimerix Acquires Lead Compound Library of Antiviral Agents from University of Michigan RESEARCH TRIANGLE PARK, NC, May 24 2006 - Chimerix, Inc., an emerging biotechnology company developing orally available antiviral therapeutics, announced today that it has acquired Dr.
Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it
Chimerix Raises $11 Million SAN DIEGO, CA, November 4, 2004 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the
